查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047908

禽流感治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭格局分類，2021-2031年

Bird Flu Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球禽流感治療市場預計將從 2025 年的 261.5 億美元成長到 2031 年的 430.9 億美元，複合年成長率為 8.68%。

該市場涵蓋多種抗病毒藥物和疫苗，旨在預防和控制人類及禽類的禽流感感染。推動市場成長的關鍵因素包括高致病性病毒感染率的上升，以及為應對大規模家禽死亡對全球糧食安全造成的威脅而迫切需要採取措施。此外，各國政府為因應潛在的通用感染疾病而採取的儲備醫療物資的策略，也大大促進了市場發展，使其不受產業暫時波動的影響。

市場概覽
預測期 2027-2031
市場規模：2025年 261.5億美元
市場規模：2031年 430.9億美元
複合年成長率：2026-2031年 8.68%
成長最快的細分市場 聯合療法
最大的市場 北美洲

然而，流感病毒的快速變異是市場擴張的一大障礙，因為為了維持其有效性，需要頻繁且高成本進行產品重組。這種不穩定性體現在，儘管目前已採取了相關措施，但流感病毒仍對動物族群造成了嚴重影響。根據世界動物衛生組織（OIE）預測，到2025年4月，一場高致病性禽流感疫情將導致全球約376萬隻家禽死亡或被撲殺。如此持續的損失凸顯了應對不斷變異的病毒株並維持有效防治措施的挑戰。

市場促進因素

全球衛生部門正積極加強生物防禦策略，大量儲備先進疫苗，以減輕疫情大流行的潛在影響。這種主動採購的策略轉變正為製藥公司帶來豐厚回報，因為各國政府都致力於確保傳統疫苗和新一代疫苗的生產能力。資金正被迅速撥付，以加快mRNA候選疫苗的核准，與傳統的雞蛋培養方法相比，mRNA疫苗具有更優異的擴充性。例如，2024年7月，Moderna公司從美國生物醫學高級研究與發展局（BARDA）獲得1.76億美元的津貼，用於加速其mRNA流感大流行疫苗的臨床開發。這筆資金確保了必要的資源能夠集中用於對抗禽流感，並確保供應鏈能夠應對激增的需求。

高致病性病毒爆發的日益頻繁，尤其是涉及跨物種傳播的爆發，使得控制哺乳動物族群中的病毒攜帶者成為當務之急。病毒向牲畜的傳播帶來了複雜的挑戰和持續的通用感染疾病威脅，需要強力的抗病毒措施和持續監測。哥倫比亞廣播公司新聞（CBS News）在2024年10月報道稱，該病毒已在美國14個州的250多個酪農確診，進一步凸顯了農業領域的這一風險，增加了農業工人的感染風險。為了應對這一問題，國際組織正在達成有針對性的採購協議。特別是，歐盟委員會於2024年與CSL公司簽署了一項框架協議，供應66.5萬劑疫情前疫苗，以保護獸醫和高風險人員。

市場挑戰

流感病毒的高變異率對全球禽流感治療市場的持續成長構成重大障礙。由於病毒株不斷演變，現有的抗病毒藥物和疫苗存在失效風險，迫使製藥公司投入持續且資源密集的研發週期。頻繁的產品更新需求推高了營運成本，延緩了穩定治療方法的上市，最終擠壓了利潤空間，並阻礙了產業高效擴大生產規模的能力。

此外，病毒的不斷變異正威脅市場穩定，其傳播速度遠超有效應對措施的實施速度。儘管已有干預措施，但疫情仍在全球持續蔓延，顯示傳統治療方法不足以遏制疾病的擴散。根據世界動物衛生組織（OIE）的數據，到2024年，高致病性禽流感將影響全球82個國家和地區。如此廣泛的地域覆蓋凸顯了在病毒不斷變異導致現有治療方法的有效性持續下降的情況下，維持市場持續成長所面臨的巨大營運挑戰。

市場趨勢

人工智慧驅動的基因組監測技術的引入，透過實現超越傳統監測技術的預測建模，正在徹底改變禽流感的檢測方式。這項技術進步使衛生部門能夠分析來自電子健康記錄和環境樣本的大量資料集，從而在潛在的感染疾病識別出來。透過將機器學習演算法與基因測序通用，研究人員可以檢測到原本可能被忽略的高風險傳播途徑。 2025年8月，馬裡蘭大學醫學院報告稱，一個生成式人工智慧模型成功識別出76名疑似高風險接觸過該病毒的急診門診病人，而這些患者如果通過標準的臨床篩檢程序則會被遺漏。

同時，「同一健康」策略框架的整合正在透過促進機構間合作，彌合動物、人類和環境健康領域之間的差距，從而改變市場格局。這種綜合方法超越了被動應對，建立了一種能夠應對病毒在不同物種之間複雜傳播的同步反應機制。各國政府正為這種合作模式投入資金，以加強地方和州級層級快速資訊共用和協調干預策略的基礎設施。例如，2025年1月，美國疾病管制與預防中心（CDC）撥款超過2億美元，用於幫助衛生機構實施有針對性的「同一健康」方法，以進行農場監測和調查。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球禽流感治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（抗病毒藥物、合併療法、預防性抗生素、Ribavirin）
    • 依最終使用者（診所、醫院、院內醫療中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美禽流感治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲禽流感治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區禽流感治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲禽流感治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲禽流感治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球禽流感治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GSK PLC
  • Hoffmann-La Roche Inc
  • Forest Pharmaceuticals Inc
  • BioCryst Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19541

The Global Bird Flu Treatment Market is projected to expand from a valuation of USD 26.15 Billion in 2025 to USD 43.09 Billion by 2031, reflecting a compound annual growth rate of 8.68%. This market encompasses a range of antiviral medications and vaccines aimed at preventing and managing avian influenza infections in both humans and avian species. The primary catalysts for this growth include the rising incidence of high-pathogenicity viral outbreaks and the urgent necessity to protect global food security against mass poultry mortality. Additionally, government strategies focused on stockpiling medical countermeasures to prepare for potential zoonotic transmission offer robust support for market development, independent of temporary industry fluctuations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 26.15 Billion
Market Size 2031USD 43.09 Billion
CAGR 2026-20318.68%
Fastest Growing SegmentCombination Treatment
Largest MarketNorth America

However, the rapid mutation rate of influenza viruses poses a major obstacle that could hinder market scalability by necessitating frequent, expensive product reformulations to maintain efficacy. This volatility is highlighted by the disease's severe impact on animal populations despite current interventions. As reported by the World Organisation for Animal Health, approximately 3.76 million poultry birds died or were culled worldwide in April 2025 due to outbreaks of high pathogenicity avian influenza. Such persistent losses emphasize the significant challenge of maintaining effective control measures against constantly evolving viral strains.

Market Driver

National health authorities are actively enhancing biodefense strategies by acquiring large stockpiles of advanced vaccines to mitigate the potential impact of pandemic scenarios. This strategic shift towards preemptive procurement is generating significant revenue for pharmaceutical companies, as governments seek to secure manufacturing capabilities for both conventional and next-generation vaccine platforms. Financial resources are being swiftly allocated to expedite the licensure of mRNA candidates, which offer better scalability than traditional egg-based production. For example, Moderna received a $176 million award from BARDA in July 2024 to further the clinical development of its mRNA pandemic influenza vaccine, providing the capital needed to focus resources on avian flu solutions and ensure supply chain resilience against demand surges.

The rising frequency of high-pathogenicity outbreaks, particularly those involving cross-species transmission, has created an urgent need to control viral reservoirs within mammalian populations. The virus's expansion into livestock creates a complex challenge, establishing a persistent threat of zoonotic spillover that requires strong antiviral measures and continuous monitoring. Underscoring this agricultural risk, CBS News reported in October 2024 that the virus had infected over 250 dairy herds in 14 U.S. states, increasing exposure risks for farm workers. To address this, international organizations are executing targeted purchasing agreements; notably, the European Commission signed a framework contract with CSL in 2024 for the supply of 665,000 pre-pandemic vaccine doses to safeguard veterinarians and at-risk personnel.

Market Challenge

The high mutation rate of influenza viruses acts as a significant hurdle to the sustainable growth of the Global Bird Flu Treatment Market. Because viral strains are in a state of constant evolution, current antiviral drugs and vaccines are at risk of losing their potency, forcing pharmaceutical manufacturers into continuous, resource-intensive research and development cycles. The requirement for frequent product updates drives up operational expenses and delays the market launch of stable therapeutic options, ultimately squeezing profit margins and hampering the industry's capacity to scale production efficiently.

Moreover, the virus's persistent evolution threatens market stability by outpacing the deployment of effective countermeasures. The failure of static treatments to halt the disease is demonstrated by its ongoing global spread despite available interventions. Data from the World Organisation for Animal Health indicates that high pathogenicity avian influenza impacted 82 countries and territories worldwide in 2024. This widespread geographic reach highlights the immense operational difficulty involved in sustaining consistent market growth when the fundamental efficacy of treatments is continually compromised by viral adaptation.

Market Trends

The deployment of AI-powered genomic surveillance is revolutionizing the detection of avian influenza by facilitating predictive modeling that surpasses conventional monitoring techniques. This technological advancement allows health officials to analyze massive datasets from electronic medical records and environmental samples to identify potential zoonotic spillover events before they escalate into widespread outbreaks. By combining machine learning algorithms with genomic sequencing, researchers can detect high-risk transmission pathways that might otherwise go unnoticed. In August 2025, the University of Maryland School of Medicine reported that a generative AI model successfully flagged 76 emergency department patients with potential high-risk viral exposure who had been missed by standard clinical screening protocols.

Simultaneously, the integration of One Health strategic frameworks is reshaping the market by fostering interagency collaboration that bridges the gap between animal, human, and environmental health sectors. This holistic approach moves beyond reactive measures to establish synchronized response mechanisms capable of addressing the complex interface of viral transmission among diverse species. Governments are committing financial resources to this collaborative model to enhance infrastructure for rapid information sharing and coordinated intervention strategies at local and state levels. For instance, the Centers for Disease Control and Prevention allocated more than $200 million in January 2025 to assist health departments in implementing a targeted One Health approach for farm-based surveillance and investigation.

Key Market Players

  • GSK PLC
  • Hoffmann-La Roche Inc
  • Forest Pharmaceuticals Inc
  • BioCryst Pharmaceuticals, Inc.

Report Scope

In this report, the Global Bird Flu Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bird Flu Treatment Market, By Type

  • Antivirals
  • Combination Treatment
  • Prophylactic Antibiotics
  • Ribavirin

Bird Flu Treatment Market, By End-User

  • Clinics
  • Hospitals
  • Institutional Health Centers
  • Others

Bird Flu Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bird Flu Treatment Market.

Available Customizations:

Global Bird Flu Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bird Flu Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Antivirals, Combination Treatment, Prophylactic Antibiotics, Ribavirin)
    • 5.2.2. By End-User (Clinics, Hospitals, Institutional Health Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Bird Flu Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bird Flu Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-User
    • 6.3.2. Canada Bird Flu Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-User
    • 6.3.3. Mexico Bird Flu Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-User

7. Europe Bird Flu Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bird Flu Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-User
    • 7.3.2. France Bird Flu Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-User
    • 7.3.3. United Kingdom Bird Flu Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Bird Flu Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-User
    • 7.3.5. Spain Bird Flu Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-User

8. Asia Pacific Bird Flu Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bird Flu Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-User
    • 8.3.2. India Bird Flu Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-User
    • 8.3.3. Japan Bird Flu Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-User
    • 8.3.4. South Korea Bird Flu Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-User
    • 8.3.5. Australia Bird Flu Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-User

9. Middle East & Africa Bird Flu Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bird Flu Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-User
    • 9.3.2. UAE Bird Flu Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-User
    • 9.3.3. South Africa Bird Flu Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-User

10. South America Bird Flu Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bird Flu Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-User
    • 10.3.2. Colombia Bird Flu Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-User
    • 10.3.3. Argentina Bird Flu Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bird Flu Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GSK PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Hoffmann-La Roche Inc
  • 15.3. Forest Pharmaceuticals Inc
  • 15.4. BioCryst Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer